Le Lézard
Classified in: Health
Subjects: NPT, FDA

FDA Approves New Drug to Treat Diabetes-Related Kidney Disease

NEW YORK, Sept. 30, 2019 /PRNewswire/ -- "The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that their drug INVOKANA® (Canagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 diabetes and chronic kidney disease (CKD). It is the first new treatment for diabetic kidney disease (DKD) to be approved by the FDA in decades."

NKF Logo (PRNewsfoto/National Kidney Foundation)

"The National Kidney Foundation applauds Janssen for bringing forth this new treatment and urges patients to discuss the implications of this new option with their healthcare professionals."

"Earlier this year, NKF brought together a group of clinicians, researchers, patients and FDA representative for a two-day, workshop titled 'The Role of the Kidney and SGLT2 in Glucose Homeostasis and Kidney Disease.'  The American Journal of Kidney Diseases will publish in the future a summary of the recommendations from the workshop. Several initiatives to inform patients and healthcare professionals will soon be launched as a result of the workshop."

"Diabetes and CKD are common and complex disorders, which often co-exist, and each are associated with multiple comorbid conditions and higher risk for mortality.  SGLT2s are proteins found in the kidneys that are important in the reabsorption of glucose by the kidneys. INVOKANA, a SGLT2 inhibitor that has been used for glycemic control in people with diabetes by inhibiting renal reabsorption of glucose, has now been shown to reduce the risk of kidney failure and heart disease in this population."

"Diabetes is a key risk factor for chronic kidney disease, and accounts for 44 percent of all end stage renal disease cases. However less than 40 percent of those with diabetes are completely assessed for kidney disease.  Two simple tests, an eGFR (which assesses kidney function) and an ACR (which assesses kidney damage) can diagnose kidney disease, and these tests results are also strong predictors of cardiovascular risk.  For information about CKD, diabetes and cardiovascular risk, see NKF's comprehensive 'Chronic Kidney Disease Change Package: Population Health Strategies for Cardiovascular and Kidney Disease Risk Reduction' report for clinicians and public health practitioners announced in January 2019."

Kidney Disease Facts
In the United States, 37 million adults are estimated to have chronic kidney disease?and most aren't aware of it.  1 in 3 American adults are at risk for chronic kidney disease.  Risk factors for kidney disease include diabetes, high blood pressure, heart disease, obesity and family history.  People of African American, Hispanic, Native American, Asian or Pacific Islander descent are at increased risk for developing the disease.  African Americans are 3 times more likely than Whites, and Hispanics are nearly 1.5 times more likely than non-Hispanics to develop end stage renal disease (kidney failure).

The National Kidney Foundation (NKF) is the largest, most comprehensive and longstanding organization dedicated to the awareness, prevention and treatment of kidney disease. For more information about NKF visit www.kidney.org.   


SOURCE National Kidney Foundation

These press releases may also interest you

at 04:32
WuXi AppTec is pleased to announce that they are about to launch the second session of the webinar series "Collaborations That Transform," highlighting the impact of partnerships in bringing effective therapies to patients. This complimentary...

at 04:30
Citi, acting through Citibank N.A., has been appointed by Amryt Pharma Plc ("Amryt") ? a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and...

at 04:10
NATIONAL OFFICE ? BKD CPAs & Advisors developed and launched a unique tool called BKDTrackForward to help healthcare organization leaders monitor Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Provider Relief Funds. The CARES Act has...

at 04:05
ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the...

at 04:00
Materia ("Materia" or the "Company"), a medical cannabis and CBD wellness company focused on the European market, today announced an agreement with Pure Ratios Holdings Inc. ("Pure Ratios"), an award-winning CBD topical manufacturer and subsidiary of...

at 03:33
IRLAB announced today that a scientific paper reporting the distinctive pharmacological profile of IRL752, in development for the treatment of impaired balance and falls in Parkinson's disease, is accepted and published online in the Journal of...

News published on 30 september 2019 at 09:47 and distributed by: